Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Bangladesh case study on how we implemented a connected diagnostics solution using GxAlert for infectious disease surveillance, TB program optimization and leveraging diagnostic data.
GxAlert Papua New Guinea Case Study 072518SystemOne
GxAlert's use in Papua New Guinea for disease surveillance and response. Initially used for Tuberculosis response, device management and second-line drug forecasting and stockage.
Feasibility of an SMS intervention to deliver tuberculosis testing results in...SystemOne
Pre-treatment loss to follow-up is common for patients diagnosed with tuberculosis (TB) in high-burden countries. Delivering test results by SMS is increasingly being considered as a solution, but there is limited information about its feasibility as a public health tool in low resourced settings. It was found that reporting Xpert results via automated SMS is technically feasible and results in approximately half of patients receiving their test results immediately. Additional research should be done to address process inefficiencies in order to maximize impact of this technology and link its successful utilization to improved patient outcomes.
GxAlert for Real-time Management and Strengthening of Remote GeneXpert Networ...SystemOne
Real-time monitoring of GeneXpert machines can contribute to reduced error rates and shorter turnaround
times for module replacement and can improve the overall
maintenance of the machines. Emails and SMS alerts can speed
up treatment initiation. The NTP now gets SMS alerts and emails for DR-TB patient enrollment; stockout and error (>5%) rates; critical module errors; and monthly MDR reports to ensure better
connections among diagnosis, enrollment, and treatment.
Bangladesh case study on how we implemented a connected diagnostics solution using GxAlert for infectious disease surveillance, TB program optimization and leveraging diagnostic data.
GxAlert Papua New Guinea Case Study 072518SystemOne
GxAlert's use in Papua New Guinea for disease surveillance and response. Initially used for Tuberculosis response, device management and second-line drug forecasting and stockage.
Feasibility of an SMS intervention to deliver tuberculosis testing results in...SystemOne
Pre-treatment loss to follow-up is common for patients diagnosed with tuberculosis (TB) in high-burden countries. Delivering test results by SMS is increasingly being considered as a solution, but there is limited information about its feasibility as a public health tool in low resourced settings. It was found that reporting Xpert results via automated SMS is technically feasible and results in approximately half of patients receiving their test results immediately. Additional research should be done to address process inefficiencies in order to maximize impact of this technology and link its successful utilization to improved patient outcomes.
GxAlert for Real-time Management and Strengthening of Remote GeneXpert Networ...SystemOne
Real-time monitoring of GeneXpert machines can contribute to reduced error rates and shorter turnaround
times for module replacement and can improve the overall
maintenance of the machines. Emails and SMS alerts can speed
up treatment initiation. The NTP now gets SMS alerts and emails for DR-TB patient enrollment; stockout and error (>5%) rates; critical module errors; and monthly MDR reports to ensure better
connections among diagnosis, enrollment, and treatment.
Ancillary Revenue Program - Are you still sending out these tests to an outside lab? UTI/STI • Vaginitis • Respiratory • ENT/Sinus • Wound • GI related infections. Find out how to CAPTURE OUTSIDE LAB REVENUE and improve patient experience and outcomes. (8) tests a day generates you over $30K in bottom-line revenue & advances patient care with a 1-hour test result that includes antibiotic resistance read-out.
https://optimalhealthadvocates.com/
UROLOGY • OB/GYN • INTERNAL MEDICINE • PRIMARY CARE • URGENT CARE • PEDIATRICS • ENT/ALLERGY • WOUND CARE
PROVEN PROGRAM:
✅ Over 100 Established Locations across the United States -- each generating at least $30K/month in bottom-line revenue.
✅ ELIMINATE delayed or ineffective antibiotic treatment & costly last-minute surgery cancellations (1-hour turn-around for results with antibiotic resistance read-out);
✅ Keep your providers compliant with CDC Antibiotic Stewardship Program (that is soon to be mandated in the clinical setting) with our program's monthly reports that will increase your facility health score by showing you are reducing the use of unnecessary antibiotics with PCR testing that is 96% more accurate than a traditional culture.
We handle ALL of the upfront capital costs, billing, staffing, and CLIA licensure/compliance at NO UPFRONT COST TO THE PRACTICE -- All that’s required is a 6-foot workspace to run the tests.
To LEARN MORE and SEE IF YOUR PRACTICE QUALIFIES, Book a 10-min Discovery Call with Jen here:
https://go.oncehub.com/Advanced_In-Office_PCR_Lab_Discovery-Call
Optimal Health Advocates as an Ancillary Medical Practice Revenue Generation company helping medical practices capture significant revenue increases while improving patient lives and outcomes.
--------------
Jennifer Anderson is a 20-year Practice Manager, entrepreneur, and digital marketing expert who intimately understands the challenges of the business of medicine and is passionate about helping Medical Sales Companies and Medical Practices successfully implement systems and services that enhance and save patient lives and increase practice revenue.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
Advisor Live: Advancing Antimicrobial StewardshipPremier Inc.
Fight antibiotic resistance! Join us and participate in Get Smart About Antibiotics Week 2016. Medical epidemiologist Dr. Kavita Trivedi will share her deep wealth of knowledge to help your organization implement and meet the challenges of antimicrobial stewardship.
- Current regulatory environment
- Implementation tools available
- Implementation challenges
NS1450X - Computerized Systems in Clinical ResearchJudson Chase
I am guest lecturer (paid) at the Boston College William F. Connell School of Nursing (more information at http://www.bc.edu/schools/son/aboutus.html).
Three or four times a year I lecture on the application of Computerized Systems in Clinical Research; this is my course deck from 2014.
10 most trusted clinical laboratories in 2021Merry D'souza
To honor the diligent services of clinical laboratories, we came up with this edition of Insights Care - 10 Most Trusted Clinical Laboratories in 2021.
2016 11-17 Oncology by design 2016 course, Amsterdam, Alain van GoolAlain van Gool
Lecture on the the role of biomarkers in oncology drug development, given to a group of pharmaceutical industry specialists, in tandem with a lecture on oncology companion diagnostics given by Martina Kaufmann.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
Keynote address to illustrate the great developments and innovations in biomarkers for personalized medicine and health, but also stressing we as scientists should pay attention to the quality of our output so results can be reproduced and implemented.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Ancillary Revenue Program - Are you still sending out these tests to an outside lab? UTI/STI • Vaginitis • Respiratory • ENT/Sinus • Wound • GI related infections. Find out how to CAPTURE OUTSIDE LAB REVENUE and improve patient experience and outcomes. (8) tests a day generates you over $30K in bottom-line revenue & advances patient care with a 1-hour test result that includes antibiotic resistance read-out.
https://optimalhealthadvocates.com/
UROLOGY • OB/GYN • INTERNAL MEDICINE • PRIMARY CARE • URGENT CARE • PEDIATRICS • ENT/ALLERGY • WOUND CARE
PROVEN PROGRAM:
✅ Over 100 Established Locations across the United States -- each generating at least $30K/month in bottom-line revenue.
✅ ELIMINATE delayed or ineffective antibiotic treatment & costly last-minute surgery cancellations (1-hour turn-around for results with antibiotic resistance read-out);
✅ Keep your providers compliant with CDC Antibiotic Stewardship Program (that is soon to be mandated in the clinical setting) with our program's monthly reports that will increase your facility health score by showing you are reducing the use of unnecessary antibiotics with PCR testing that is 96% more accurate than a traditional culture.
We handle ALL of the upfront capital costs, billing, staffing, and CLIA licensure/compliance at NO UPFRONT COST TO THE PRACTICE -- All that’s required is a 6-foot workspace to run the tests.
To LEARN MORE and SEE IF YOUR PRACTICE QUALIFIES, Book a 10-min Discovery Call with Jen here:
https://go.oncehub.com/Advanced_In-Office_PCR_Lab_Discovery-Call
Optimal Health Advocates as an Ancillary Medical Practice Revenue Generation company helping medical practices capture significant revenue increases while improving patient lives and outcomes.
--------------
Jennifer Anderson is a 20-year Practice Manager, entrepreneur, and digital marketing expert who intimately understands the challenges of the business of medicine and is passionate about helping Medical Sales Companies and Medical Practices successfully implement systems and services that enhance and save patient lives and increase practice revenue.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
Advisor Live: Advancing Antimicrobial StewardshipPremier Inc.
Fight antibiotic resistance! Join us and participate in Get Smart About Antibiotics Week 2016. Medical epidemiologist Dr. Kavita Trivedi will share her deep wealth of knowledge to help your organization implement and meet the challenges of antimicrobial stewardship.
- Current regulatory environment
- Implementation tools available
- Implementation challenges
NS1450X - Computerized Systems in Clinical ResearchJudson Chase
I am guest lecturer (paid) at the Boston College William F. Connell School of Nursing (more information at http://www.bc.edu/schools/son/aboutus.html).
Three or four times a year I lecture on the application of Computerized Systems in Clinical Research; this is my course deck from 2014.
10 most trusted clinical laboratories in 2021Merry D'souza
To honor the diligent services of clinical laboratories, we came up with this edition of Insights Care - 10 Most Trusted Clinical Laboratories in 2021.
2016 11-17 Oncology by design 2016 course, Amsterdam, Alain van GoolAlain van Gool
Lecture on the the role of biomarkers in oncology drug development, given to a group of pharmaceutical industry specialists, in tandem with a lecture on oncology companion diagnostics given by Martina Kaufmann.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
Keynote address to illustrate the great developments and innovations in biomarkers for personalized medicine and health, but also stressing we as scientists should pay attention to the quality of our output so results can be reproduced and implemented.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Nw biotech fundamentals day 2 session 4 medical devices and diagnosticsNicholas Weston Lawyers
In this presentation:
• Definition of Medical devices and Diagnostics
• The stages of an R&D project
• The state of the art
• Regulatory nuances
• Future trends
• Challenges and opportunities
• Case studies and examples
MicroGuide app, pop up uni, 1pm, 3 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
Jane Blower, Deputy Chief Scientific Officer (Acting) NHS England. Jane's presentation from the Seven Day Services event in the East Midlands on 12th June 2014.
Josephine Briggs, MD
Director
National Center for Complementary and Alternative Medicine
National Institutes of Health
Opening Keynote "Research in an IT Connected World: Building Better Partnerships – NIH and Health Care Systems"
The era of ‘Big Data’ has arrived for biomedical research, bringing with it immense challenges as well as spectacular opportunities. NIH is establishing major programs with the potential to transform the future of US biomedical research by building the capacities necessary for these challenges. These programs will strengthen research partnerships with health care systems and the IT networks that support them.
The Big Data to Knowledge (BD2K) initiative, to be launched in 2014, will implement a set of recommendations from the Data and Informatics Working Group to the Advisory Committee to the Director. Investments are planned to meet scientific needs to manage and utilize large complex datasets, including strengthening training, and investing in improved analysis methods and software development and dissemination. NIH is also evaluating strengthening data and software sharing policies, and the potential creation of catalogs of research data, and data/metadata standards.
The Common Fund’s Health Care Systems (HCS) Research Collaboratory program has the goal to strengthen the national capacity to implement cost-effective large-scale research studies by engaging major health care delivery organizations as research partners. The aim of the program is to provide a framework of implementation methods and best practices that will enable the participation of many health care systems in clinical research. Research conducted in partnership with health care systems is essential to strengthen the relevance of research results to health practice. Seven demonstration projects, currently in a feasibility phase, are developing detailed methods to implement rigorous randomized studies of questions of major public health impact. These studies, and the IT infrastructure that will make them possible, will be described in detail.
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
Targeting lipids: a primary and secondary care perspectiveInnovation Agency
Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.
Supporting the optimal detection and management of BP in Primary CareInnovation Agency
Presentation by Jane Briers, Programme Manager - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Dr Lauren Moorcroft, GP Partner - Brookvale Practice at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Introduction to Supporting recovery in Primary Care using Proactive Framework...Innovation Agency
Presentation by Julia Reynolds, Associate Director for Transformation - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Paul Brain, Project Manager at the Excel in Health series - Introduction to data webinar on Monday 6 June 2022.
In this session we discussed how SMEs can use data to grow their business and access new opportunities in the market.
Presentations by Mike Kenny, Acting Co-Director of Enterprise and Growth, Innovation Agency and Dr Neil Paul, a GP and Board Member with Cheshire East ICP at the Excel in Health: Understanding the NHS Landscape webinar on Wednesday 11 May 2022.
LCR and Cheshire and Merseyside Health MATTERS networking eventInnovation Agency
Master slide deck from the LCR and Cheshire and Merseyside Health MATTERS networking event on Wednesday 24 November 2021 at Sci-Tech Daresbury Laboratory.
Master slide deck from the Excel in Health webinar series: The NHS landscape presentation.
This webinar identifies the structure of the NHS and its national priorities.
The session will cover the following topics:
Understand the structure of the NHS
Understand the national priorities of the NHS
Recognise the barriers to sale
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
8. How does it attract business?
Lab and office accommodation for business with links to:
Category 3 labs Key Opinion Leaders
Insectaries Academics
Grid Computing Route to market
Trial unit & tissue bank Bigger business
AHSN & NHS Innovation Investors
9. Disease Resistance
• Too difficult box
• Ignored diseases
• High R & D costs
• Not met through traditional businesses
• Cancer, Diabetes, Infection, Mental health
Accelerator has a strong focus
11. House keeping
• No fire alarms planned
• No food and drink in the drum
• Introverts – ask questions at:
• www.sli.do
• Enter code: #Accelerator
Accelerator
12. Contact me on:
Dr Steve Powell
Accelerator
T: 07768 178 341
E: steven.powell@rlbuht.nhs.uk
13. Munir Pirmohamed
David Weatherall Chair of Medicine
Department of Molecular and Clinical Pharmacology
Institute of Translational Medicine
University of Liverpool
Precision Medicine
14. Current Paradigms
As physicians, we all “personalise” treatments
We use the best evidence available to us (usually
from RCTs – population based studies) to treat the
patient (i.e. individual) consulting us
From a population perspective, that has proven
benefits
But from an individual perspective, it is less
satisfactory
Cannot predict whether the patient will
improve
Cannot predict whether the patient will
develop side effects
Sir William Osler (1849-1919)
“Variability is the law of life”
15. Definition of Precision Medicine
Precision medicine is an emerging approach for disease treatment and prevention
that takes into account individual variability in genes, environment, and lifestyle for
each person
2015
Obama’s Precision
Medicine Initiative
$215 million
19. Sensors
Conventional engine control unit – dozens of data points/sec
Flight data recorders – 3000 data points/sec (2GB per flight)
Newborn baby – in 1952 APGAR test introduced – 5 data points – this is
what we use today!
"Before AliveCor it was really frustrating trying
to get doctors to take me seriously because I am
young and healthy, but I knew something wasn't
right. AliveCor FINALLY got their attention and
now I am being treated."
Change in doctor-patient relationship
21. Serious Adverse Drug Reactions
Toxic Epidermal Necrolysis
Hepatocellular hepatitis
22. HLA-B*57:01 and Abacavir Hypersensitivity
CHANGE IN INCIDENCE OF ABACAVIR HYPERSENSITIVITY
AFTER INTRODUCTION OF PROSPECTIVE GENOTPYING
Cost effective
24. HLA Platform
Mr SPOT
Histomatch software
Standard type of wells with the SSO
spotted on to the base of the well in a set
pattern which can be recognised by the
Histomatch software
25. Analytic Validation
Platform was able to call risk alleles with 100% accuracy at all the
loci (n=187 healthy volunteers)
85% have at
least 1 risk allele
Use
• At time needed
• Store data on EHR
• Pre-emptive genotype
Number of Risk Alleles per
sample
Number of Samples
% of
samples
0 28 15.0
1 39 20.9
2 14 7.5
3 46 24.6
4 34 18.2
5 11 5.9
6 6 3.2
7 8 4.3
8 1 0.5
28. GWAS Warfarin Mean Weekly Dose
(UK Prospective Cohort; n=714)
CYP2C9
VKORC1
Total = 57.9%
Age: 11.2%
Height 3.56%
Weight: 5.98%
Interacting meds: 0.98%
Sum of interacting meds: 2.2%
VKORC1: 25.61%
CYP2C9: 16.65%
CYP4F2: 0.49%
29. Warfarin RCT (NEJM, 2013)
• EU-PACT
• UK/Sweden
• 7% improvement in
time in therapeutic
range at 3 months
30. VK
*3
*2
ParaDNA: Point of Care Device
1. Take sample
2. Use device to transfer and
seal sample into four wells
pre-loaded with single or
multiplex test chemicals
3. Four separate
independent
analyses possible
4. Analysis is complete in
45 minutes.
30Courtesy of LGC, Commercial in Confidence
Sample Dispense
Three genotyping tests
(VKORC1, CYP2C9*2, *3)
31. Next Steps
Interim analysis of implementation study – evaluate effect size and cost-
effectiveness
Engage with commissioners
Engaging with NHS England
LGC introduced to American researchers with a view to developing POC
testing for African-American alleles
New study about to start in Uganda and South Africa
Potential for interacting in the Far East
Introduction to world-wide markets because of our reputation in this area.
32. RECRUITMENT LOCATION ENGAGEMENT GENETICS
Aims to recruit 3000 healthy
volunteers, of which 1000
participants from this cohort
to be of Chinese origin.
Current participant
recruitment rates indicate
that the target should be
achieved by March 2018.
Recruitment has begun at two
sites across the country. Both
NHS & Non-NHS sites are being
utilised for recruitment. Royal
Liverpool Hospital & Convance
CRO (Leeds) in partnership to
achieve study objectives
Leeds
Liverpool
Development of a active
community for volunteers to
enhance recruitment into future
phase I studies irrespective of
their location. Social media tools
will harness the real time access
to information a study of this
type requires.
DNA will be genotyped for
polymorphisms in drug
metabolizing enzymes and
transporter genes. This genotype
profile has the potential to then
be utilised when developing
generic pharmacokinetic models
predicting doses according to
genotype
33. Personalised (Precision) Health
University wide research theme
A lot of interest all over the world- but quite a lot is aspirational
In certain areas, in Liverpool, we have already delivered
Plans going forward is to further engage with Industry
Pharma Diagnostics
Devices Informatics
34. • Regulation of Genomics (MHRA)
• Health Economics for Stratified Medicine
(Academy of Medical Sciences)
• Re-engineering of clinical pathways to
facilitate implementation of personalised
medicine (NHSE)
Addressing the challenges of
delivering stratified medicine
35. Innovate UK Case Study
- MAST Diagnostics
Presented by Jon Hobson
Date: 27/06/17
36. MAST GROUP Ltd.
• SME (c.130 employees)
• Manufacturer of in vitro
diagnostic products (IVDs)
• Established in 1957
• Located in Bootle,
Merseyside
• 4 Locations Servicing
over 70 countries
37. Celebrating 60 years as an independent manufacturer
and supplier of laboratory tests for the diagnosis of
infectious disease
38. Celebrating 60 years as an independent manufacturer
and supplier of laboratory tests for the diagnosis of
infectious disease
“After 60 years we must be doing something right”
39. McDonald T, Pearson N, Johnson F, O‘Grady FW. J Med Eng Tech. 1981; 5: 243-245
Introducing Automation
Involvement in automation began in 1983
with the launch of the Mastascan system
The system evolved into the current urine
screening system developed from a
University of Liverpool KTP programme
40.
41. • Approximately 75% of urines specimens processed in
Greater London are interpreted using a
• From 1,500 entries throughout the UK
43. An Opportunity
Loop-mediated isothermal amplification (LAMP)*:
• A novel isothermal gene amplification method
• Four specific primers recognise six distinct regions of the target DNA
• Characterised by self priming DNA synthesis and visible end point
• Driven by large fragment Bst DNA polymerase with enhanced strand
displacement activity
• Suited to Point of Care/Point of Need testing
* Licensed under International Patent application numbers:. WO 00/28082, WO 01/34790, WO 01/34838,
WO 01/83817, WO 01/77317, WO 02/24902, WO 02/103053
and corresponding patents owned by Eiken Co., Ltd., Japan in other countries.
44. Remit: A point of care assay for detection
of Neisseria gonorrhoeae and Chlamydia
trachomatis from a urine sample in a
clinic
Time to result: 1 hour
Rationale: To be able to prescribe
appropriate treatment before the patient
leaves
Looking for a Solution
47. Industrial and lead partner: commercial exploitation,
development of assay reagents and diagnostic platform
Sample preparation, culture of organisms,
determination of limits of detection
Optical readout, molecular diagnostic platform software
and electronics design
Clinical input and evaluation, molecular assay development
Expertise of Project Partners
48. • Managing the project
• Frequency of meetings
• Skype calls
• Quarterly reports and meetings
• Appointed monitoring officer
Structuring the Project
49. Comprised of clinicians and sexual health workers
• Extension of project scope
• Definition of sample type
• Provided essential feedback on development
The Focus Group
50. • PhDs awarded: one each at UoL and LJMU, (embargos on theses)
• Peer-reviewed articles and IP creation (Patents granted)
• Conference presentations
• Reagent methodologies and Diagnostic platform
• Assay exploitation (LJMU): Food authenticity testing
• MAST ISOPLEX® Lyo kits
Product & IP Outcomes
51. Urine
Sample
Nucleic Acid
Extraction
Amplification of
target using
LAMP*
Real time analysis of
optical output
All steps conducted in a single
point of care device
* Licensed under International Patent application numbers:. WO 00/28082, WO 01/34790, WO 01/34838, WO 01/83817,
WO 01/77317, WO 02/24902, WO 02/103053 and corresponding patents owned by Eiken Co., Ltd., Japan in other countries.
The Diagnostic Assay
52. Benchtop extraction
On-device extraction
Time (1 unit = 1/88th of one minute)
9 mins
23 mins
Target 1:100fg
TARGET 2 :100fg
Target 3: 10^1 copies
Target 4:1pg
Target 5: 100fg
Target 6:100fg
Target 7: 1pg
Extraction & Amplification Efficiency
56. Growing long term relationships
Developing innovative products
Building multidisciplinary teams
Providing mutually beneficial outcomes
Managing expectations
What We Learnt
57. Growing long term relationships
Providing mutually beneficial outcomes
Developing innovative products
Building multidisciplinary teams
Managing expectations
What We Learnt
Continuing “to do something right” to the next Anniversary
61. What is Sensor City?
• A Liverpool-based technical innovation centre and University Enterprise Zone.
• Fostering the creation, development, production and promotion of cutting
edge sensor technologies for use in a range of sectors.
• Operating out of a 2,500m2 purpose-built technical and business support
centre, designed to meet the needs of our industry partners (opens June 2017).
• A collaboration between University of Liverpool and Liverpool John Moores
University.
62. A Flagship University Enterprise Zone
Sensor City Liverpool Limited
– £5m BEIS
– £5m ERDF (ESIF 2014-20)
– £2m industry match
– £1.5m from both Liverpool John Moores University and University of Liverpool
63. Vision
By working collaboratively, and creating a connected sensor
community, we aim to make Liverpool a global hub for sensor
technologies.
64. Sensor City objectives
– Provide purpose-built accommodation in a city centre innovation hub
– Increase SME innovation
– Integrate an established academic base with industry
– Establish and support a connected sensor community
68. Sensor City facilities
– State-of-the-art equipment and technical support
.
– Technology development zone
• Integrated open laboratory services
• Software development support
• Electronics lab
• Shared equipment
• ..
– Open innovation lab with ‘sandpit’ model to support problem solving,
innovation and collaborative design
.
– Shared meeting rooms, workshop and break out areas
.
– Located close to universities and access to further facilities
69. Sensor City support
– Academic expertise
– Entrepreneurship coaching
– Business mentoring
– Networking support & events
– Industry-partnered student
internships
– Access to funding & scholarships
– Active investor network
71. • Non-ionising
• Good penetration
• Relatively inexpensive
• Good versatility
– Designs to suit application
• We have developed many
different types of sensor to
suit different usage.
Electromagnetic Wave Sensing
74. Some theory…
Port1
Port2
Input
power
S11 (reflected power)
Microwave
Cavity
S21 (transmitted power)Port1
Port2
Sample
22
2
d
l
a
pc
f nm
rr
nml
A change in sample εr results
in shift of resonant frequency
Pozar, D. M. 1998. Microwave Engineering 2nd Edition, John Wiley & Sons, ISBN 0471170968.
77. Non-invasive wireless sensors to track
physiologic signs and biochemical
markers
Left, experimental setup, showing participant on ergometer with sensors attached and appropriate data
acquisition hardware; right illustrates placement of sensors on both arm and leg with another participant.
80. Enuresis Detection
(a) is an image with
a dry sensor
(b) is a photo 1 sec later as the
Urine has been placed on the
sensor showing the prototype
communicating wirelessly to a
mobile phone through Bluetooth.
Graph showing the sensor output distinguishing
between sweat, water, urine and urea concentration.
81. Enuresis Prediction
Photos of prototype 2 working at 868MHz with a smaller footprint and also
movement and temperature sensors incorporated for prediction algorithm
Sensor
Movement
sensor board
Microcontroller
and temperature
sensor
Frequency generation
and detection board
82. Cannula Monitoring
• 85% of all hospital patients have a
cannula: 29% of these cause
infiltration and extravasation with
minor to major effects
• From Jan 2013 to Dec 2015, 64
severe cases recorded at Alder
Hey
• We propose a disposable wireless
sensor placed over the cannula
dressing to detect water
differentials that change due to
extravasation
88. Diverse models of collaboration
• Universities
• Commercial research (fee for service)
• Collaborative research, including
• Consortia
• Post-docs
• PhDs/KTPs
• Placements
• NHS
• Early phase units
• Clinical trials
89. Mechanistic Understanding of Adverse Drug
Reactions
University case study:
Centre for Drug Safety
Science
Slide from UoL
90. CDSS approach to improving drug safety
Chemistry of
the Drug
Biology of the
System
Variability of
the Patient
Improving
Drug Safety
Science
Safe Drug
Design
Innovative Use
of Bioanalysis
Organ-directed
Toxicity
Predictive
Models
Mechanistic
Biomarkers
Role of the
Immune System
Pharmacogenetics
of ADRs
HLA Restriction
Chemical Stress
Slide from UoL
91. Working with Industry
Partner in several IMI-JU projects
SAFE-T: clinical validation of organ-injury biomarkers
MIP-DILI (Managing Entity): new model systems for predicting DILI
Web-RADR: social media and big data in pharmacovigilance
SafeSciMet: European safety Masters training
TransQST (Co-ordinator): quantitative systems toxicology
Several company-sponsored investigative projects for drug-specific ADRs
CASE studentships
All supported by a dedicated Industry Programme Manager
https://www.liverpool.ac.uk/drug-safety/
Slide from UoL
94. Funding Your Collaboration
LJMU Funding
(& UoL/LSTM too)
BBSRC LINK BBSRC Industry Partnership Award
MRC Industry Collaboration Award Innovate UK Knowledge Transfer Partnership
Slide from LJMU
95. NHS research – National Institute for Health Research (NIHR)
• NHS
• Early phase units
• NIHR Royal Liverpool & Alder Hey
• Clinical trials
• NIHR Clinical Research Network North West Coast
97. NHS research – National Institute for Health Research (NIHR)
• NIHR Clinical Research Network North West Coast
• Provides infrastructure that allows high-quality clinical
research to take place in the NHS
• Help to increase opportunities for patients to take part in
clinical research and ensure that studies are carried out
efficiently
99. www.liverpoolhealthpartners.org.uk
• Development of commercial research partnerships
• Maximise clinical trial recruitment opportunity for patients
• Deliver to time & target recruitment
• Gateway for PI’s/CI’s across Liverpool City region
Liverpool Health Partners - Industry Gateway Office
Slide from LHP
112. a specialist business support and services company
Delivering tangible value to the biomedical sector in the North of England
Members include:
biotech, pharmaceutical, analytic, CRO, CMO, diagnostics, healthcare
and medical device companies plus the specialist supply chain
Our service spans procurement, insurance, recruitment, training, specialist
events and access into a vibrant network of businesses, Universities and the NHS
Bionow’s corporate and university sponsors share our vision for long term growth
Together we enable Bionow member organisations to be
the most productive and competitive in the world
113. Bionow Membership & Reach
• Bionow is the membership organisation for life science
businesses in the North
• 280+ subscribing members.
• Major corporates through to small SME members - AZ
corporate patron.
• Direct links with 1000+ businesses across the North
• Contacts at 3000+ life science businesses across the UK.
• Deliver events to 2000+ delegates annually.
• Significant national linkages – United Life Sciences – BIA,
One Nucleus, UKTI LSO, OLS, BIS, KTN, Innovate UK etc.
• Significant regional linkages - 8 Northern University
sponsors & 7 University Premium Members; NHSA; N8;
AHSNs; LEPs, key science parks & innovation centres etc.
114. Bionow Business Support
Bionow offers a suite of integrated business support services including:
• Mentoring
• Access to the NHS
• Lifescience Launchpad / Medtech Accelerator
• Knowledge Transfer Partnerships
• Student Placements and Projects
For more information visit
http://www.bionow.co.uk/support.aspx
115. Infrastructure for engagement
Bionow website www.bionow.co.uk
Members can Post News
Search/Post Jobs
Browse and Register for Events
Business B2B networking platform www.bionowb2b.co.uk
Members can create tailored ‘microsite’ to position a targeted sector message
Will shortly become a fully searchable version of the Bionow Directory
Social media
Bionow Ltd https://twitter.com/bionow
https://www.youtube.com/user/bionowchannel
Monthly Newsletter – available to all
Bi-monthly Member Review - 4Members
116. Some of our events in 2017/18
• Precision Medicine Conference – 5th April – Leeds
• Liverpool John Moores’ Showcase event, 16th May 2017
• Medtech Accelerator – 7 half days 12th April to 5th July, Daresbury
• BioFocus – 29th June 2017, Centre for Life, Newcastle
• R&I Event – Manchester Metropolitan University – 6th July
• Daresbury Business Pitching, 11th July
• School Career days – August
• BioCap 2017 and Investor Dinner – 27th & 28th September, Alderley Park
• BioInfect 2017 and pre-event Dinner 1st & 2nd November, Alderley Park
• BioEurope, 6th – 8th November, coordinating Northern Powerhouse presence with NHSA
• Bionow Annual Awards 2017 – 30th November, The Mere
• Genesis – exhibiting in London Dec 2017 as part of Northern presence
• Oncology event, Alderley Park, 28th February
• National specialist supply chain event with One Nucleus 2018
• All events at www.bionow.co.uk/events
117. The North
• Northwest, Northeast and
Yorkshire
• Includes the city regions of
Liverpool, Manchester, Lancaster,
Sheffield, Leeds, York, Durham &
Newcastle
• Described in the Bionow
Northern Life Science and
Healthcare Directory
• 1000 life science and healthcare
businesses
118. North of England life science companies
Strength & Opportunity 2013 (without pharma)
628
694
626
358
503
348
258
336
246
135
271
61
841
0 100 200 300 400 500 600 700 800 900
East of England
South East
West Midlands
Yorkshire and the Humber
East Midlands
North West
Wales
Scotland
South West
North East
London
Northern Ireland
The North
Company numbers across UK regions
The North
• 1000+ life science and healthcare
businesses
• Combined turnover £10.9bn
• Employment of 38,000
• Exports of £7.3 billion medicinal and
pharmaceutical products in 2015 equating
to 44.7 per cent of UK exports
119. Biotech and
Pharmaceutical
21%
CRO
10%
CMO
6%
Diagnostics
8%
Analytical
9%
Medical Technology
26%
Healthcare
15%
Industrial / Agri Biotech
5%
Northern company base
Around 25% of the total number of life science businesses in the UK – good
representation across the value chain
Category Numbers of Companies in the
North
Biotech and Pharmaceutical 98
CRO 47
CMO 30
Diagnostics 39
Analytical 42
Medical Technology 119
Healthcare 72
Industrial / Agri Biotech 21
Core Company Total 468
Specialist supply chain 531
Total 999
Manufacturing strengths in all these
subsectors – with particular hubs in NW (Speke
& Macclesfield) and the Northeast
120. Particular industrial strengths of the North
• (Pharma, chemical, vaccine, bio) Manufacturing
• Biotech & Pharma
• Specialist supply chain (CRO, CMO, Analytics etc.)
• Infection (incl. AMR)
• Precision Medicine (incl. diagnostics)
• Management & delivery of clinical trials
• Wound care & orthopaedics
• Med Tech
• Digital Health
121. Northwest company base
Biotech
15% Pharmaceutical
8%
CRO
12%
CMO
5%
Diagnostics
8%
Analytical
7%
Medical Technology
22%
Healthcare
21%
Industrial / Agri Biotech
2%
A leading (top 3) UK region with a full offering across the value chain – from
discovery to market
122. Particular industrial strengths in Liverpool
An important cornerstone in the Northern Powerhouse with key strengths in:
• (Pharma, chemical, vaccine, bio) Manufacturing – a key centre
• Major strengths in translational infection research – CEIDR, LSTM
• Precision Medicine (incl. diagnostics)
• Management & delivery of clinical trials
• Med Tech
• Digital Health
Lots of synergies with the North and lots of examples of companies working
globally and growing their businesses..
123. A few examples of growing, connected businesses in
Liverpool
Liverpool ChiroChem - supply chiral compounds to pharmaceutical research companies across North of England and
beyond.
Videregen - Part of Horizon 2020 research project in regenerative medicine
Evgen plc – AIM listing and have multi-centre Phase II clinical trial in patients with ER+ metastatic breast cancer
Mast Group – Innovate UK grants, extensive range of microbiology and immunology products and global network
Pro Lab Diagnostics - European HQ, distribute and manufactures products within the immunodiagnostics area. A
strategic alliance with the Animal & Plant Health Agency and part of the worldwide Pro-Lab Group.
Plus Major Corporates:
125. A functioning health partnership for the North of England
To maximize the impact of health science
research and to provide a go-to center for
healthcare companies we have created the
Northern Health Science Alliance (NHSA), a
collaboration between eight of England's great
cities across a population of 15m people.
126. Precision Medicine Population / Digital HealthHealthy Ageing
Research Themes
eHEALTH & DATA ANALYTICSCLINICAL TRIALS & Health Economics
• Two Precision Medicine Catapults
• Four Genomic England Centres
• Two NIHR Diagnostic Evidence Cooperatives (Leeds /
Newcastle)
• Two MRC / EPSRC Pathology Nodes
• New Medicines Technology Catapult
• Two MRC Single Cell Genomic Centres
• The UK AMR Centre at Alderley Park
• Cancer Research UK Manchester Institute
• Cancer Research UK Leeds Centre
• Cancer Research UK Newcastle Centre
• Astbury Centre (Leeds)
• National Centre for Ageing Science & Innovation in Newcastle
• MRC Arthritis UK Centre for Integrative Musculoskeletal
Ageing
• NIHR Newcastle Biomedical Research Centre in Ageing &
Chronic Disease
• Alder Hey Children’s Hospital
• York Neuroimaging Centre (YNiC)
• Centre for Hyperpolarisation in Magnetic Resonance (CHyM)
• SITraN in Sheffield
• Centre for Ageing Research (Lancaster)
• NIHR funded centres for Public Health research
• ESRC Centre for Translational Research in Public
Health
• Institute of Infection & Global Health, University of
Liverpool
• Well North
• Three NHS England Test Beds
• Liverpool John Moores University's Research
Institute for Sport and Exercise Sciences (RISES)
• CATCH in Sheffield
• NIHR Clinical Research Networks
• Several Clinical Research Facilities, three in Manchester alone
• MRC Network of Hubs for Trials Methodology Research
• Sheffield School for Health Related Research
• York Health Economics
• NWeHealth FARSITE trials recruitment tool
• MRC eHerc, Farr Institute, NorthWest eHealth at Manchester
• MRC Medical Bioinformatics Centre in Leeds
• EPSRC Postgraduate Centre for Cloud Computing in Newcastle
• Sci-Tech Daresbury and The Hartree Centre
• eHealth SME cluster (Liverpool City Region)
• Connected Health Cities
• CHICAS, School of Health and Medicine.
Key Health Research Themes in the North
Digital Health approaches and technologies are deployed across
all research themes.
127. The North of England has a thriving life science sector
• Health and life science sector
accounts for £17.5 billion of
the North’s £305 billion
output (GVA)
• It is forecast to grow by
44.6% by 2030.
• The sector employs over
570,000 people with over
38,000 of those in highly
skilled private sector
positions across 1,000 life
science companies.
128. The Northern Triple Helix via N8, NHSA & Bionow
Academic, clinical and industrial engagement across the North:
• Under the “Life Science in the Northern Powerhouse” brand at national and international events e.g.
Genesis, BioTrinity, BIO International, Bio Europe etc.
• Regional activities such as joint conferences (e.g. Precision Medicine & Cancer)
• Coordinated responses to Government e.g. on Northern Powerhouse initiatives.
• Aimed at increased academic, clinical and industry engagement to drive economic growth and patient
benefit.
129. In summary…
• The North is a cluster of international scale with the Northwest representing
the cornerstone to this.
• There are opportunities & strengths across the whole value chain.
• Liverpool is a key component of the Northern cluster.
• International businesses locating here have found it a low risk place to do
business.
• The business support infrastructure is second to none, focused upon delivery
and high quality space is readily available.
• The support ecosystem is well connected, co-ordinated and collaborative and
aimed at de-risking business investment.
• .…plus it’s a great place to live and work!
131. AIMES Digital Health &
Research Infrastructure
Dr. Ed Conley
Chief Scientific Officer, AIMES,
Liverpool Innovation Park
Connected Health Cities Programme
ed.conley@aimes.net
Accelerating the
Translation of
Medical Research
27th June 2017
132. AIMES’ Core Interests
- Digital services for
learning health
systems and cross-site
federated
research
- Regional-scale
Health
Information Exchange
- Secure connectivity
and EPR system hosting
133. Pharma
133
Patients/
Citizens
Payers
Universities
Government &
Public Health
Local
Healthcare
Delivery
Systems
(Patient journey)
Research
Institutes
Biomedical
Data
Tech Industry
Learning Health
System Stakeholders
ALL PRODUCE AND
CONSUME DATA
Learning Health Systems Interfacing Challenge
participant consumers/producers of data and the research community
GPs, Consultants, Research Nurses
NHS Information Services, NHS Managers
Social Care, Ambulance, Emergency Services…
Strategic Planning
/Policy
3rd Sector organisations
Clinical Guideline
Committee Chairs
Local Authority
Innovation Agency
ABPI EHR & Medical
Device Vendors
Commissioning
Groups (CCGs)
Scientists
Technologists
Researchers
Statisticians
RECORD
HOSTING
& TRE
137. AIMES Digital Health &
Research Infrastructure
Dr. Ed Conley
Chief Scientific Officer, AIMES,
Liverpool Innovation Park
Connected Health Cities Programme
ed.conley@aimes.net
Accelerating the
Translation of
Medical Research
27th June 2017
140. Cerno Health is the master distributor for United Imaging in the UK & Republic of Ireland
Dr. Min Xue, Chairman of the Board & Chief Executive Officer, UIH
and Mr Gary Disley, Managing Director, Cerno Health following
the signing of the Master Distributor agreement in Shanghai, China.
141.
142.
143. Exclusive Distributor of UIH equipment in the UK & the Republic of Ireland
CERNO HEALTH LTD
Media House : Boyton Hall : Roxwell Road: Chelmsford : Essex : CM1 4LN : United
Kingdom
T: +44 333 301 0312 F: +44 333 301 0311
E: info@cernohealth.com W: www.cernohealth.com
145. Vector Biology an Example
• Malaria
• Dengue
• Leishmaniasis
• Trypanosomiasis
• Zika
• Chikungunya
146. Text
Novel Interventions and Enabling Technologies
for Insect Borne Disease Prevention
Challenges and approaches
to encourage
the development
of innovative
vector control tools
147. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
IVCC is a Product Development
Partnership investing donor funds in
R&D to overcome barriers to
innovation in vector control
IVCC supports the malaria elimination
and eradication agenda with a focus
on bringing new tools and products to
failed markets that can combat the
rapidly growing problem of insecticide
resistance
A new Vector Control Product Development Partnership (PDP)
148. Bridging Public Health Needs and Innovation Barriers
Translational Focus
Development Focus
151. Projects require partnership with Industry and Academia, overseen by Expert
Scientific Advisory Committees (ESACs)
ESAC
oard of Trustees
ESAC1
0
2
4
6
8
10
Efficacy
Implementati…
Safety
Regulatory
IP
End User…
Ability to…
Resistance…
Spectrum
Speed of…
Environment…
Cost of Goods
Toxicology
Mode of action
152. Impact of Northern Ghana
• Actellic CS developed by
Syngenta is the first long lasting
non-pyrethroid IRS formulation
( 3rd Generation IRS)
• We supported trials to
demonstrate safety and efficacy
allowing early adoption by PMI
• Initial data from PMI
implementation shows
outstanding impact
Bunkpurugu-Yunyoo district, Northern Ghana
Control program data from Abt and PMI, In preparation for publication
155. Developing and applying DNA markers to predict
insecticide resistance
0
5
10
15
20
25
30
35
40
0 500 1000 1500
Moshi alive (resistant) vs Tarime (susceptible)
• Risk of insecticide failure is a major challenge for disease control and can be aided by widespread,
high volume data from molecular diagnostics to feed into disease management systems
• We apply transcriptomic and genomic approaches to discover markers for insecticide resistance in
wild caught vectors
• Markers are tested for predictive value and geographical relevance
156. Public Health Products
• Indoor Residual Treatments
• Long lasting nets
• Tiny Targets
• Larvicides
157. Examples of application and challenges
Increase in Ace-1 marker in Anopheles gambiae predicts extreme resistance
to carbamate insecticides in southern Ghana
Possession of kdr resistance markers by sandflies P. argentipes
predicts human blood feeding in Bangladesh
Human Non-human
Wild
type
(blue)
Marker development also
underway for Aedes.
Challenge: how to apply
information in urban, rather
than rural settings more
typical for malaria and
leishmaniasis
158. • Improving diagnostics
• Defining the spectrum of
neurological disease
• Mosquito control
• Understanding the
immune response to
develop treatments and
vaccines
Liverpool Response to
Zika Outbreak in Latin America
161. What are AHSNs?
We are licenced by NHS England to:
• Speed up adoption of innovation into practice to improve clinical outcomes
and patient experience
• Support economic development through co-development, testing,
evaluation and early adoption and spread of new products and services
Focusing on the needs of patients and local populations and building a culture
of partnership and collaboration
162. National Reach and Local Delivery
• Nationally we collaborate as a strong network of 15 - operating across health and
care to deliver improvement at pace and scale. Collectively we support an number
of national programmes including
• NHS Innovation Accelerator
• Health SBRI
• Innovation Pathway
• Patient Safety Collaboratives
• Locally we act as honest brokers within our regions, mobilising expertise across the
NHS, academia and industry to help improve lives, save money and drive economic
growth.
163. Who do we work with?
Nationally
• NHS England, NHS Improvement and the Department of Health / Public Health England and Office for Life Sciences
• Representative bodies such as the ABHI and ABPI (representing industry), NHS Clinical Commissioners and NHS Providers
• NICE
• Third sector organisations such as charities and patient representative groups
Locally
• NHS provider trusts
• Clinical Commissioning Groups and other commissioning organisations
• Public health and social care organisations including local authorities
• Local transformation partnerships such as Sustainability and Transformation Partnerships (STPs)
• Local Universities and NIHR organisations such as CLAHRCs, Clinical Research Networks and Biomedical Research Units / Centres
• Local NHS organisations such as Strategic Clinical Networks and Senates
• Local Economic Partnerships
• Industry and cluster groups such as MediLinks, Bionow
165. Idea Proof of concept Adoption Spread
Innovation and Technology Payment (NHSE)
Central reimbursement of innovative products, services
and technologies
NHS Innovation Accelerator (NHSE)
Supporting a small number of fellows to spread
their innovations in the NHS
Accelerated Access Partnership (OLS)
Comprised of cross health economy stakeholders, supporting the development of transformative
products, services and technologies via existing routes
NHS Apps Library (NHSD)
Setting standards for apps looking to be
used in the NHS
Health Apps Briefing (NICE)
Assessment of the economic and
efficacy of apps
Test Beds (NHSE)
Pioneering and evaluating the use of novel combinations of
interconnected devices
Small Business Research Initiative (NHSE)
Provides funding to develop innovative ideas to NHS problems
Invention for Innovation (NIHR)
Provides funding for development of
prototypes
There are a number of initiatives supporting the identification and adoption of
innovative products, services and technologies
OLS
NHSE
NIHR
NICE
NHSD
166. National Innovation Accelerator
Apply: http://nhsaccelerator.com/
Applications will be accepted from 14 June 2017 to midnight on 26 July 2017.
Interview dates: 26 – 28 September 2017.
Confirmation: Successful applicants will be contacted on 12 October 2017.
167. The Innovation and Technology
Payment (ITP)
• The ITP aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake
of innovative products or technologies.
• Competitive process to identify innovations and technologies that will offer the greatest quality and efficiency
benefits with wider adoption.
• The ITP is looking to support medical devices, digital platforms and technologies. The programme is not suitable
for pharmaceutical products or research projects.
• select a range of cost effective innovations within budgetary confines
• a wide-reaching impact on patient care
• maximise learning and foster culture change.
• ITP is specifically focused on low cost innovations which can deliver significant patient outcomes and savings to
the NHS.
• The programme will be delivered in partnership with the AHSNs, sponsors, national and international experts.
• Applicants can be from healthcare, academia, commercial or voluntary sectors.
• Agreed payment mechanism or procurement will be operational from April 2018.
• Day-to-day support and reporting via NHS E’s Innovation and Research Unit.
168. SBRI Health
SBRI Healthcare is an NHS England funded initiative led by the Academic Health Science Networks to develop
technology solutions for known healthcare challenges. Our focus for Summer 2017 is Cancer, screening and
accelerated diagnosis as well as solutions for improved management of those who have survived.
• Applications for innovations that can enhance the screening, diagnosis or management of cancer.
• Up to £100,000 of funding for Phase one (feasibility) and up to £1m for Phase Two (development)
• A truly innovative offer that could transform screening, diagnosis or management of cancer.
• NHS needs will be provided in an SBRI Healthcare briefing document available the week commencing 24th July,
with briefing events London on Tuesday 25th and Manchester on Thursday the 27th.
The deadline for entries will be 4th September. Register at www.sbrihealthcare.com to receive the full briefing
and details (available from 25th July).
169. STOPandGO
Sustainable Technology for Older People – Get
Organised
• Public Procurement of Innovative Solutions (PPI)
01/04/14 – 31/01/18
• Benefit to 5000 people across Europe
• 15 Partners in Spain, Italy, the Netherlands and the UK
• FP7 contributes €3.446m to existing commitment
€17.23m
• Liverpool City Council due to receive minimum €600,000
(may rise to €1.2m)
• 4000 Domiciliary Care beneficiaries receive electronic
care plan
170. RITMACORE
Arrhythmias Monitoring and Comprehensive
Care
• Public Procurement of Innovative Solutions (PPI)
01/11/16–31/12/20
• 9 partners in the UK, Spain, Italy and the Netherlands
• H2020 contributes €4m to €7.5m of existing
commitment
• Liverpool Heart and Chest to receive c €1m towards
remote monitoring
• Warrington Hospital as a potential participant €500k+
171. ENSAFE
Elderly-oriented, Network-based Services
Aimed at Independent Life
• Funded under H2020 Ambient & Assisted Living
Programme
• SE, IT, NL and UK partners piloting integrated
technology solution
• Aims to introduce new products to market 2 years
after project end
• Focus on the technology vs commercialisation
opportunities
172. • Largest healthcare initiative in the world-H2020
• 130 Partners (IBM, Roche, Sanofi, universities, research institutes)
• Aims to:
o Promote entrepreneurship
o Innovate in healthy living and active ageing
o Improving quality of life in healthcare across Europe
173. Three EIT Health Programmes:
Innovation; Campus; Accelerator
• Campus 2017- Digital Hospital Transformation Short Course 29/08/17-01/09/17
Budapest
o Digital healthcare trends and technologies and design of transformation
project
• Accelerator 2017 – Product Market Fit
o 15 awards of €25,000 for start-ups (restrictive criteria)
• Accelerator 2017– Proof of Concept/Headstart
o Local SME (Damibu) in receipt of €50,000 award
174. Applications submitted
• Innovation by Ideas – xFall (Falls prevention technologies and innovative
approaches)
o Research Institutes Sweden (RI.SE), University Polytechnic Madrid, Skane
Municipality and the Royal Pharmaceutical Society €2m (€248k 2018, €215k
2019)
• Innovation by Design - Make Health Fluidics Contest
• Commission for Atomic Energy (Fr), Medical Valley (De) etc €480k (€27k 2018)
• Accelerator – P/M Fit (improved criteria – SMEs not start-ups)
• Accelerator – Headstart/PoC 15 applications from SMEs
175. NIHR – i4i Mental Health Challenge
• To develop innovative technological solutions
that can influence the patient care pathway
and improve patient outcomes for mental
health conditions
• Winner takes all approach
• £5m application with Mersey Care - Suicide
and self harm reduction for people in their
care
176. Horizon 2020
The EU Framework Programme for Research
and Innovation
• Supported the submission of a proposal from
LJMU to H2020 (plus Aimes and Glow Media)
• ICAN – Personalised coaching for well-being
and care of people as they age
• 3 year proposal - €100k for IA
177. Next steps?
• Horizon scanning for funding opportunities
• Partners – ECH Alliance / EIP AHA / others?
• Priorities
• Knowledge assets
• Leaders in their field
• Specialist facilities
• Project (application) Champions
178. Next Steps for AHSNs proposed future
model 2018-2023
Role of the
AHSN
1
NHS
EnglandGovernment
NHS Improvement
Partner
Contributions, EU
funding, industry
funding, grants etc
Deliver AAR objectives – support
local assessment of technologies
and knowledge exchange;
promote spread of innovation
nationally.
Translate research into practice and build
stronger relationships with the
scientific/academic communities and
industry to develop solutions to
healthcare problems. Deliver Five Year
Forward View, Genomics advances, Test
Beds, Innovation and Technology
Payment, Digital Health, Diagnostics,
Medicines Optimisation.
Partnerships with academic and
research institutions, NHS
providers, commissioners, industry.
Coordination of the 15 Patient Safety
Collaboratives to improve the safety of patients.
Delivery of Developing People, Improving Care
Role of
AHSN
Network
179. In Summary
• AHSNs are catalysts for the spread of innovation at pace and scale - improving health,
generating economic growth and helping facilitate change across whole health and social care
economies
• AHSNs connect - as member organisations we are well placed to mobilise cross-sector
buy-in, developing powerful regional networks of NHS and academic organisations, local
authorities, third sector and industry: responding to diverse patient and population needs
through partnership & collaboration
• AHSNs create the right environment for relevant industries to work with the health and
social care system
181. THE IMPORTANCE OF INTERNATIONAL BUSINESS & INVESTMENT
Ellen Cutler Director of Investment Invest Liverpool
Health & Life Sciences lead contact:
Matt Biagetti
mbiagetti@investliverpool.com @mattbiagetti LinkedIn.com/in/mattbiagetti